AstraZeneca succeeds in last-ditch bid to stop former executive starting at GSK this week
AstraZeneca has succeeded in an eleventh-hour effort to stop a former senior executive from joining rival GSK this week after a High Court judge granted the drugmaker an injunction in an unusual legal battle featuring Britain’s two biggest pharmaceutical companies.
Chris Sheldon, who left AstraZeneca in August after holding several senior roles, was due to start at GSK on September 1 with responsibility for development across the group’s therapy businesses.
AstraZeneca sued Sheldon in July, alleging that starting at GSK before February would put him in breach of a non-compete agreement that was due to run for six months.
This story originally appeared on: Financial Times - Author:Donato Paolo Mancini
